- Home
- DHAI vs ARMP Comparison
DHAI vs ARMP Comparison
Compare DHAI & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- ARMP
- Stock Information
- Founded
- DHAI 2007
- ARMP N/A
- Country
- DHAI United States
- ARMP United States
- Employees
- DHAI N/A
- ARMP N/A
- Industry
- DHAI
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DHAI
- ARMP Health Care
- Exchange
- DHAI NYSE
- ARMP Nasdaq
- Market Cap
- DHAI 49.1M
- ARMP 52.1M
- IPO Year
- DHAI N/A
- ARMP N/A
- Fundamental
- Price
- DHAI $0.22
- ARMP $2.01
- Analyst Decision
- DHAI
- ARMP Strong Buy
- Analyst Count
- DHAI 0
- ARMP 1
- Target Price
- DHAI N/A
- ARMP $9.00
- AVG Volume (30 Days)
- DHAI 1.2M
- ARMP 624.1K
- Earning Date
- DHAI 07-14-2025
- ARMP 05-14-2025
- Dividend Yield
- DHAI N/A
- ARMP N/A
- EPS Growth
- DHAI N/A
- ARMP N/A
- EPS
- DHAI N/A
- ARMP N/A
- Revenue
- DHAI $69,573,000.00
- ARMP $4,699,000.00
- Revenue This Year
- DHAI N/A
- ARMP $8.43
- Revenue Next Year
- DHAI N/A
- ARMP N/A
- P/E Ratio
- DHAI N/A
- ARMP N/A
- Revenue Growth
- DHAI 5.40
- ARMP 14.24
- 52 Week Low
- DHAI $0.12
- ARMP $0.90
- 52 Week High
- DHAI $3.67
- ARMP $3.42
- Technical
- Relative Strength Index (RSI)
- DHAI 52.62
- ARMP 58.73
- Support Level
- DHAI $0.21
- ARMP $1.90
- Resistance Level
- DHAI $0.28
- ARMP $2.20
- Average True Range (ATR)
- DHAI 0.03
- ARMP 0.33
- MACD
- DHAI 0.00
- ARMP 0.03
- Stochastic Oscillator
- DHAI 57.14
- ARMP 55.46
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.